Nezavist
| Clinical data | |
|---|---|
| Other names | DCUK-OEt; DCUKA ethyl ester; DCUK ethyl carboxylate |
| Routes of administration | Oral[1] |
| Drug class | Peripherally selective GABAA receptor positive allosteric modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H19Cl2N3O3 |
| Molar mass | 480.35 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Nezavist, also known as DCUK-OEt, is a peripherally selective GABAA receptor positive allosteric modulator which is under development for the treatment of alcoholism and depressive disorders.[1][2][3][4] It is taken orally.[1] The drug is a positive allosteric modulator (PAM) specifically of the etomidate allosteric site of the GABAA receptor.[4] As it does not cross the blood–brain barrier, Nezavist is peripherally selective and does not directly produce central nervous system effects.[3] Nonetheless, the drug has been found to reduce alcohol self-administration in rodents, perhaps via intestinal stimulation of the vagus nerve.[4] Nezavist is under development by Lohocla Research.[1][2] As of October 2025, it is in phase 1 clinical trials for alcoholism and the preclinical research stage of development for depressive disorders.[1][2]
See also
References
- ^ a b c d e "DCUK OEt". AdisInsight. 10 October 2025. Retrieved 18 May 2026.
- ^ a b c "Delving into the Latest Updates on Nezavist with Synapse". Synapse. 8 May 2025. Retrieved 18 May 2026.
- ^ a b Hoffman PL, de Guglielmo G, Vengeliene V, Kunze W, Lebonville CL, Swinny JD, et al. (March 2026). "Engaging Gut-to-Brain Signalling to Treat Alcohol Use Disorder". Addiction Biology. 31 (3) e70144. doi:10.1111/adb.70144. PMC 13093268. PMID 41879717.
- ^ a b c Simeone X, Khom S, Doppler AM, Seidel T, Scholze P, Tabakoff B, et al. (January 2026). "Nezavist (DCUK-OEt) and aminoquinoline analogues interact with the etomidate site and display a complex mode of modulatory action of the GABAA receptor". European Journal of Pharmacology. 1012 178464. doi:10.1016/j.ejphar.2025.178464. PMID 41419089.